2020 Partners Included
We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC-induced protein degradation: compound binding and permeability, ternary complex formation, ubiquitination, and trafficking to proteasome. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Founded in 1990, Schrödinger has nearly 400 employees and operations across the world.
LifeSensors generates reagents and drug discovery platforms which enable researchers to accurately and effectively assay the Ubiquitin Proteasome System. In addition to off-the-shelf products and kits, LifeSensors also partners with companies and researchers around the world to develop novel drug discovery assays. LifeSensors’ powerful technologies in conjunction with our expertise in the UPS, have enabled researchers to target and assay the undruggable targets.
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule targets Acute Myeloid Leukemia (in clinic Q2 2019) and our lead Protein Homeostatic Modulator (PHM™) will be in the clinic Q3 2020 for hematological malignancies.
Bio-Techne brings together some of the most referenced brands in life science to provide innovative tools for Targeted Protein Degradation. Boston Biochem are world leaders in ubiquitin-proteasome system-related products, Tocris Bioscience are market leaders for research tool Degraders and Degrader building blocks while ProteinSimple provide automated platforms for detecting and quantifying protein degradation via Western Blot.
Together we are Bio-Techne. Find out how we can help you achieve your research goals.
At MilliporeSigma, our purpose is to solve the toughest problems in life science. To accelerate discovery for Targeted Protein Degradation, our Sigma-Aldrich Chemical Biology portfolio simplifies synthesis and library generation of protein degraders with degrader building blocks and custom synthesis capabilities. In addition to new degrader probes and lead discovery tools, TPD research is supported through our extensive offerings in bioactive small molecules, antibodies, western blotting, and genome editing tools such as CRISPR.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
FIDA technology quantifies and characterizes protein behaviour in complex samples including plasma, serum and fermentation media. The read-out is an absolute measure of protein/complex size in nanometers. The absolute read-out enables Determination of ternary complex size, Assessment of multiple Kd’s in formation of complex and Identification of fraction bound. It is possible to work with molecules and particles ranging 0,5-1000 nm. The technology is characterized by rapid assay development, minimal sample preparation, nanolitre sample consumption.
Syngene International Ltd
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation-focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele includes world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4240-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed up time to market and lower the cost of innovation.
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally.
GVK BIO is a global Contract Research and Development Organization (CRDO) providing research and development services to the biopharma and life sciences industry. We enable our customers to bring their products to market in a fast yet cost-efficient manner. Combining our deep expertise in chemistry and biology, we have helped accelerate the development of several targeted protein degraders (PROTACs and Molecular Glues) for our global customers, and have helped solved several scientific problems in this exciting new field.
Nanome is changing how we understand, design, and interact with science. Nanome’s immersive virtual workspaces allow users to visualize, modify, and simulate chemical compounds, proteins, and nucleic acids to help improve the Drug Discovery process. Our virtual reality platform facilitates effective communication of structural data in drug discovery which has proved beneficial to several pharmaceutical and biotech companies across the globe. This is especially helpful for organizations that are interested in improving their cross-site collaboration.
For more information, please visit: